PMID- 19002464
OWN - NLM
STAT- MEDLINE
DCOM- 20090303
LR  - 20220801
IS  - 1863-2297 (Print)
IS  - 1863-2297 (Linking)
VI  - 30
IP  - 4
DP  - 2008 Dec
TI  - Clinical impact of natural killer cell reconstitution after allogeneic 
      hematopoietic transplantation.
PG  - 489-503
LID - 10.1007/s00281-008-0136-1 [doi]
AB  - Although the optimal donor for allogeneic hematopoietic stem cell transplantation 
      is a human leukocyte antigen (HLA)-matched sibling, 75% of patients do not have a 
      match and alternatives are matched unrelated volunteers, unrelated umbilical cord 
      blood units, and full HLA-haplotype-mismatched family members. This review will 
      focus on the open issues of allogeneic hematopoietic transplantation and on the 
      benefits of natural killer (NK) cell alloreactivity and its underlying 
      mechanisms. Donor-versus-recipient NK cell alloreactivity derives from a mismatch 
      between inhibitory receptors for self major histocompatibility complex (MHC) 
      class I molecules on donor NK clones and the MHC class I ligands on recipient 
      cells. These NK clones sense the missing expression of the self MHC class I 
      allele on the allogeneic targets ("missing self") and mediate alloreactions. 
      Here, we review the translation of NK cell allorecognition into the clinical 
      practice of allogeneic hematopoietic transplantation and discuss how it has 
      opened innovative perspectives in the cure of leukemia.
FAU - Velardi, Andrea
AU  - Velardi A
AD  - Division of Hematology and Clinical Immunology, Department of Clinical and 
      Experimental Medicine, University of Perugia, Ospedale Santa Maria della 
      Misericordia, Perugia, Italy. velardi@unipg.it
FAU - Ruggeri, Loredana
AU  - Ruggeri L
FAU - Mancusi, Antonella
AU  - Mancusi A
FAU - Burchielli, Emanuela
AU  - Burchielli E
FAU - Perruccio, Katia
AU  - Perruccio K
FAU - Aversa, Franco
AU  - Aversa F
FAU - Martelli, Massimo F
AU  - Martelli MF
CN  - Immunobiology Working Party of the European Group for Blood and Marrow 
      Transplantation (EBMT)
LA  - eng
GR  - 1 P01 CA 100265-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20081111
PL  - Germany
TA  - Semin Immunopathol
JT  - Seminars in immunopathology
JID - 101308769
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Animals
MH  - Graft Rejection/immunology
MH  - Graft vs Host Disease
MH  - Haplotypes
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Leukemia/therapy
MH  - Transplantation, Homologous/*immunology
RF  - 115
EDAT- 2008/11/13 09:00
MHDA- 2009/03/04 09:00
CRDT- 2008/11/13 09:00
PHST- 2008/08/31 00:00 [received]
PHST- 2008/09/30 00:00 [accepted]
PHST- 2008/11/13 09:00 [pubmed]
PHST- 2009/03/04 09:00 [medline]
PHST- 2008/11/13 09:00 [entrez]
AID - 10.1007/s00281-008-0136-1 [doi]
PST - ppublish
SO  - Semin Immunopathol. 2008 Dec;30(4):489-503. doi: 10.1007/s00281-008-0136-1. Epub 
      2008 Nov 11.